Sterile-Site Separation Architecture Director — Specialty Pharmaceuticals

The mandate

The divested sterile site owns physical manufacture but depends on the seller for microbiology methods, qualified-person release coordination, artwork master data, serialization alerts, market complaints and cold-chain distribution contracts. The sale agreement lists transitional services by department rather than product decision. Neither party can yet show how a batch moves safely when one shared service ends or a retained market rejects the buyer’s replacement process.

The deliverable is a Regulated Site Separation Architecture covering product-and-market dependencies, decision ownership, transitional service boundaries, quality agreement changes, evidence migration, stranded interfaces, Day-One controls and service exits. It must distinguish legal separation from operational independence and define temporary bridges where immediate disentanglement would threaten release evidence, patient supply or market-authorisation obligations.

Milestone one at week four accepts the product, market and service dependency baseline; week eight closes critical quality and regulatory decisions. Day-One controls are signed by week thirteen, each transition-service exit design by week eighteen and eleven market playbooks by week twenty-three. Rehearsals occur in weeks twenty-six, twenty-nine and thirty-one before final acceptance at week thirty-two.

Acceptance requires seller and buyer owners to execute unseen scenarios involving sterility investigation, artwork change, serialization alert, qualified-person absence, cold-chain excursion and retained-market complaint without ambiguous evidence custody. The Divestiture Executive and Chief Quality Officer accept only when every critical service has an accountable successor, measurable exit condition, tested fallback and reconciled record trail independent of consultant-held knowledge.

The client will provide transaction agreements, service schedules, product registrations, quality records, laboratory methods, batch and distribution flows, complaint interfaces, technology inventories, vendor contracts and empowered seller-and-buyer owners. Exclusions include batch disposition, regulatory submissions, legal interpretation, technology configuration, method validation, workforce consultation, vendor appointment, live separation command and assurance on tax or deal consideration.

Why this is external work

Internal teams are simultaneously protecting supply, negotiating transaction language and defending legacy accountabilities. A neutral regulated-operations architect is needed to expose dependency at product-decision level, challenge both parties symmetrically and produce testable exit conditions without becoming the quality approver, transaction counsel or Day-One operator.

What you will own

• Trace each product-market path through manufacture, laboratory evidence, batch disposition, artwork, serialization, distribution and complaint response.
• Translate departmental transitional services into discrete decisions, inputs, outputs, owners, controls, volumes and expiry conditions.
• Define Day-One operating bridges where legal transfer precedes validated operational independence.
• Design exit criteria for laboratory, release, artwork, serialization, distribution and complaint services with measurable evidence.
• Build eleven market playbooks that reconcile authorisation holder, supply owner, record custodian and escalation duty.
• Rehearse sterility, artwork, serialization, qualified-person, cold-chain and complaint failures across both organisations.
• Deliver the separation architecture, service catalogue, decision matrix, control register, rehearsal evidence and accepted exit roadmap.

Candidate qualifications

• Architected pharmaceutical or biologics separations involving manufacturing, quality, laboratory and market-release dependencies.
• Converted transaction-service schedules into executable regulated decisions and evidence-backed exit criteria.
• Understood sterile operations, qualified-person interfaces, serialization, artwork, complaints and cold-chain distribution.
• Designed Day-One controls and fallbacks where system, method or vendor independence could not coincide with legal close.
• Challenged seller and buyer teams without assuming quality, regulatory, legal or executive authority.
• Transferred a separation design through client-led adverse scenarios and reconciled evidence custody between organisations.

Non-negotiables

• Can lead nine Dublin design laboratories and three rehearsals within the eight-month engagement.
• Direct regulated-site separation experience is required; generic transaction management is insufficient.
• Will disclose pharmaceutical clients, buyers, sellers, laboratories, logistics providers and transaction advisers.
• Will not release batches, interpret agreements, file submissions, validate methods, appoint vendors or command Day One.

1. 49 words maximum. Describe a transitional service whose apparent exit concealed a regulated product dependency.
2. 49 words maximum. How would you test evidence custody during a cross-company sterility investigation?
3. 49 words maximum. Which inputs must be available by week two to protect the thirty-two-week deadline?